Step-down from multiple- to single-dose proton pump inhibitors (PPIs): A prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs

American Journal of Gastroenterology

Volumn 98, Issue 9, 2003, Pages 1940-1944

  Inadomi, John M ^a   McIntyre, Lisa ^b   Bernard, Latoya ^b   Fendrick, A Mark ^b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; COST UTILITY ANALYSIS; DRUG DOSE REDUCTION; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; UNITED STATES;

EID: 0141621818     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07665.x     Document Type: Article

References (17)

1. Pharmacy Benefits Management Strategic Health Group. Contract adherence reports national reports: Q4FY99. Washington, DC: Department of Veterans Affairs, Veterans Health Administration, 2000.
2. Sontag S. Gastroesophageal reflux disease. Aliment Pharmacol Ther 1993;7:293-312.
3. Bell N, Hunt R. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33:118-24.
4. Wesdorp I, Dekker W, Festen HP. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 1993;38:2287-93.
5. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100.
6. Nyren O, Adami H, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986;314:339-43.
7. Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989;11:169-77.
8. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.
9. Farup PG, Wetterhus S, Osnes M, Ulshagen K. Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997;32:755-9.
10. Talley NJ, McNeil D, Hayden A, Piper DW. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986;91:149-56.
11. Colwell HH, Mathias SD, Pasta DJ, et al. Development of a health-related quality of life questionnaire for individuals with gastroesophageal reflux disease. A validation study. Dig Dis Sci 1999;44:1376-83.
12. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
13. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-10.
14. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995;48:1495-501.
15. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107:1305-11.
16. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
17. Fass R, Pulliam G, Johnson C, et al. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing 2000;29:125-30.